Philips has introduced the HyperVue Integrated System in the U.S., a fixed, single-room setup combining DeepOCT+NIRS imaging with X1-FFR physiology assessment for coronary interventions. This system is designed to streamline cath lab workflows by keeping advanced imaging and physiology tools permanently available, reducing setup time and complexity. It integrates angiography-derived, AI-powered coronary physiology with intravascular imaging to support precise diagnosis and treatment planning. Philips will showcase this system alongside its broader portfolio at TCT 2026, emphasizing improved workflow and patient care in complex coronary procedures.
Following Philips' launch of the HyperVue Integrated System in the U.S., the company's stock on Pluang is trading at USD 27.14 as of Oct 31, 2026 03:11 WIB, showing a modest gain of 0.39% for the day. Philips holds a market cap of $26.47 billion and offers a dividend yield of 3.74%, reflecting steady investor interest in its health sector innovations. The stock's typical hold time on Pluang is 86 days, indicating a medium-term investment horizon among platform users.
Philips has introduced UniGuide 3D Live Guidance, a new CE-marked solution that integrates CT-derived planning insights directly into live procedures using its Azurion image-guided therapy platform. This technology allows physicians to access detaile...
Philips has introduced the Lumea 9900 Pro, the first at-home IPL device featuring real-time audio feedback and motion guidance to enhance user confidence and personalization. Industry experts highlight three key trends shaping beauty tech: personaliz...
